The management of age-related macular degeneration has rapidly progressed following the development of the anti-vascular endothelial growth factor (VEGF) ranibizumab. Ongoing trials are helping to define appropriate treatment schedules to optimise the use of ranibizumab in clinical practice.
Advances in the treatment of neovascular age-related macular degeneration
LANZETTA, Paolo
2008-01-01
Abstract
The management of age-related macular degeneration has rapidly progressed following the development of the anti-vascular endothelial growth factor (VEGF) ranibizumab. Ongoing trials are helping to define appropriate treatment schedules to optimise the use of ranibizumab in clinical practice.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
